Literature DB >> 2203349

Hydrolysis of synthetic chromogenic substrates by HIV-1 and HIV-2 proteinases.

L H Phylip1, A D Richards, J Kay, J Kovalinka, P Strop, I Blaha, J Velek, V Kostka, A J Ritchie, A V Broadhurst.   

Abstract

Kinetic constants (Km,Kcat) are derived for the hydrolysis of a number of chromogenic peptide substrates by the aspartic proteinase from HIV-2. The effect of systematic replacement of the P2 residue on substrate hydrolysis by HIV-1 and HIV-2 proteinases is examined.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2203349     DOI： 10.1016/0006-291x(90)91412-l

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN： 0006-291X            Impact factor:   3.575


  9 in total

1.  Altered substrate specificity of drug-resistant human immunodeficiency virus type 1 protease.

Authors:  Deborah S Dauber; Rainer Ziermann; Neil Parkin; Dustin J Maly; Sami Mahrus; Jennifer L Harris; Jon A Ellman; Christos Petropoulos; Charles S Craik
Journal:  J Virol       Date:  2002-02       Impact factor: 5.103

2.  Analysis of cleavage site mutations between the NC and PR Gag domains of Rous sarcoma virus.

Authors:  G Schatz; I Pichova; V M Vogt
Journal:  J Virol       Date:  1997-01       Impact factor: 5.103

3.  Ordered processing of the human immunodeficiency virus type 1 GagPol precursor is influenced by the context of the embedded viral protease.

Authors:  Steven C Pettit; Jose C Clemente; Jennifer A Jeung; Ben M Dunn; Andrew H Kaplan
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

4.  Replacement of the P1 amino acid of human immunodeficiency virus type 1 Gag processing sites can inhibit or enhance the rate of cleavage by the viral protease.

Authors:  Steve C Pettit; Gavin J Henderson; Celia A Schiffer; Ronald Swanstrom
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

5.  Human immunodeficiency virus type-1 reverse transcriptase and ribonuclease H as substrates of the viral protease.

Authors:  A G Tomasselli; J L Sarcich; L J Barrett; I M Reardon; W J Howe; D B Evans; S K Sharma; R L Heinrikson
Journal:  Protein Sci       Date:  1993-12       Impact factor: 6.725

6.  Polymorphism and drug-selected mutations in the protease gene of human immunodeficiency virus type 2 from patients living in Southern France.

Authors:  P Colson; M Henry; C Tourres; D Lozachmeur; H Gallais; J A Gastaut; J Moreau; C Tamalet
Journal:  J Clin Microbiol       Date:  2004-02       Impact factor: 5.948

7.  CGP 53437, an orally bioavailable inhibitor of human immunodeficiency virus type 1 protease with potent antiviral activity.

Authors:  E Alteri; G Bold; R Cozens; A Faessler; T Klimkait; M Lang; J Lazdins; B Poncioni; J L Roesel; P Schneider
Journal:  Antimicrob Agents Chemother       Date:  1993-10       Impact factor: 5.191

8.  Caught in the Act: the 1.5 A resolution crystal structures of the HIV-1 protease and the I54V mutant reveal a tetrahedral reaction intermediate.

Authors:  Andrey Y Kovalevsky; Alexander A Chumanevich; Fengling Liu; John M Louis; Irene T Weber
Journal:  Biochemistry       Date:  2007-12-04       Impact factor: 3.162

9.  Comparative genomics of the bacterial genus Streptococcus illuminates evolutionary implications of species groups.

Authors:  Xiao-Yang Gao; Xiao-Yang Zhi; Hong-Wei Li; Hans-Peter Klenk; Wen-Jun Li
Journal:  PLoS One       Date:  2014-06-30       Impact factor: 3.240
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.